A physiological model for the estimation of the fraction dose absorbed in humans

被引:164
作者
Willmann, S
Schmitt, W
Keldenich, J
Lippert, J
Dressman, JB
机构
[1] Bayer Technol Serv GmbH, D-51368 Leverkusen, Germany
[2] Bayer AG, D-42096 Wuppertal, Germany
[3] Bayer Technol Serv GmbH, D-51368 Leverkusen, Germany
[4] Goethe Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany
关键词
D O I
10.1021/jm030999b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A physiologically based model for gastrointestinal transit and absorption in humans is presented. The model can be used to study the dependency of the fraction dose absorbed (F-abs) of both neutral and ionizable compounds on the two main physicochemical input parameters (the intestinal permeability coefficient (P-int) and the solubility in the intestinal fluids (S-int)) as well as physiological parameters such as the gastric emptying time and the intestinal transit time. For permeability-limited compounds, the model produces the established sigmoidal dependence between F-abs and P-int. In case of solubility-limited absorption, the model enables calculation of the critical mass-solubility ratio, which defines the onset of nonlinearity in the response of fraction absorbed to dose. In addition, an analytical equation to calculate the intestinal permeability coefficient based on the compound's membrane affinity and molecular weight was used successfully in combination with the physiologically based pharmacokinetic (PB-PK) model to predict the human fraction dose absorbed of compounds with permeability-limited absorption. Cross-validation demonstrated a root-mean-square prediction error of 7% for passively absorbed compounds.
引用
收藏
页码:4022 / 4031
页数:10
相关论文
共 55 条
[1]   Predicting the impact of physiological and biochemical processes on oral drug bioavailability [J].
Agoram, B ;
Woltosz, WS ;
Bolger, MB .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 :S41-S67
[2]   Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[3]   TARGETING DRUGS TO THE COLON - DELIVERY SYSTEMS FOR ORAL-ADMINISTRATION [J].
ASHFORD, M ;
FELL, JT .
JOURNAL OF DRUG TARGETING, 1994, 2 (03) :241-257
[4]   Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption [J].
Balon, K ;
Riebesehl, BU ;
Müller, BW .
PHARMACEUTICAL RESEARCH, 1999, 16 (06) :882-888
[5]   Effect of glucose and lipids on intestinal absorption of sorbitol: Role of gastric emptying [J].
Beaugerie, L ;
Lemann, M ;
Jian, R ;
Flourie, B ;
Rain, JD ;
Rambaud, JC .
NEUROGASTROENTEROLOGY AND MOTILITY, 1996, 8 (03) :235-239
[6]  
BIRCHER J, 1999, KLIN PHARM DATENSAMM
[7]  
BRENER W, 1983, GASTROENTEROLOGY, V85, P76
[8]   Shapes of membrane permeability-lipophilicity curves: Extension of theoretical models with an aqueous pore pathway [J].
Camenisch, G ;
Folkers, G ;
van de Waterbeemd, H .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (04) :321-329
[9]   Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight [J].
Camenisch, G ;
Alsenz, J ;
van de Waterbeemd, H ;
Folkers, G .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (04) :313-319
[10]   Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH [J].
Charman, WN ;
Porter, CJH ;
Mithani, S ;
Dressman, JB .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (03) :269-282